The U.S. Securities and Exchange Commission last year rejected without explanation the attempt by the The Carlyle Group L.P. to go public with a provision in its partnership agreement requiring individual arbitration instead of securities class actions.
That same year, the SEC refused to let shareholders of Pfizer Inc. and Gannett Co. Inc. advance a shareholder proposal to amend their corporate bylaws, opaquely stating in a no-action letter requested by management that the proposals might violate the securities laws, notwithstanding substantial U.S. Supreme Court precedent to the contrary.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]